Atherosclerosis: History and Discovery

Atherosclerosis — the slow build-up of fatty, fibrous plaque inside the arteries — has no single discoverer and no inventor. It is one of the oldest diseases of the human body, written into the arteries of mummies more than 3,000 years old, and its modern understanding was assembled gradually over two centuries by anatomists, pathologists, and experimentalists who often disagreed sharply. The name itself records the discovery: from the Greek athērē (gruel or porridge), for the soft yellow lipid-rich core of a plaque, joined to sclerosis (hardening), for the stiffening of the vessel wall. This page traces that cumulative story honestly — what was observed, who named what, which ideas were genuine debates, and which famous concepts began life as hypotheses and only later earned the weight of evidence.

Table of Contents

  1. An Ancient Disease: Mummies and the Horus Study
  2. Naming the Disease: Atherosclerosis and Arteriosclerosis
  3. Early Anatomy: From Leonardo to the First Descriptions
  4. The Great Debate: Virchow versus Rokitansky
  5. Anitschkow, the Rabbit, and the Lipid Hypothesis
  6. Epidemiology and the Risk-Factor Era
  7. Response to Injury and the Return of Inflammation
  8. From Hypothesis to Therapy: The Statin Story
  9. Research Papers and References
  10. Connections

An Ancient Disease: Mummies and the Horus Study

It is tempting to think of atherosclerosis as a modern affliction — a product of fast food, tobacco, and sedentary office life. The historical evidence says otherwise. Atherosclerosis is ancient, and the most striking proof comes from the arteries of the long dead. In the Horus study, an international team led by cardiologists and paleopathologists used whole-body CT scanning to look for arterial calcification — the calcium that hardens into old atherosclerotic plaque — in preserved human remains. The first phase, published in JACC: Cardiovascular Imaging in 2011, scanned 52 ancient Egyptian mummies and found definite or probable atherosclerosis in 20 of the 44 in whom arteries could be identified, including a princess who lived around 1550–1580 BCE with calcification in the very arteries that feed the heart.

The study's most important conclusion came in 2013, when it was expanded and published in The Lancet. Across four widely separated ancient populations — ancient Egyptians, the Ancestral Puebloans of the American Southwest, the Unangan hunter-gatherers of the Aleutian Islands, and the Ancient Peruvians — roughly a third of the 137 mummies examined showed signs of probable or definite atherosclerosis. These were people with vastly different diets and ways of life, including hunter-gatherers and farmers who never saw a cigarette or a processed meal. The finding strongly suggests that atherosclerosis is, at least in part, an inherent feature of human aging and not solely a disease of modern living — though modern habits clearly accelerate it.

Calcified plaques have also been reported in other ancient remains, including the famous Tyrolean Iceman (Ötzi), who carried arterial calcification more than 5,000 years ago. Taken together, this paleopathology reframes the entire history that follows: the doctors and scientists described below were not discovering a new disease but slowly learning to see, name, and explain a very old one.

Back to Table of Contents

Naming the Disease: Atherosclerosis and Arteriosclerosis

The vocabulary of the disease is itself a record of discovery, and the two key words are often confused. The broader term came first. In 1833, the French (Alsatian) pathologist Jean-Frédéric Lobstein (1777–1835), in his Traité d'anatomie pathologique, coined "arteriosclerosis" as a general label for the hardening and thickening of arteries seen at autopsy — literally "artery" plus "hardening," with no commitment to a specific cause. Arteriosclerosis remains the correct umbrella term for several distinct ways arteries stiffen with age.

The more specific term arrived seventy years later. Around 1904, the German pathologist Felix Marchand (1846–1928) introduced "atherosclerosis" to name the particular, most common, and most dangerous form — the one in which a soft, fatty, lipid-rich deposit (the athere, or gruel) accumulates within the arterial wall and the wall then hardens and narrows around it (the sclerosis). The word fuses the two defining features into one: a porridge-like core inside a hardened vessel. Marchand's coinage did real conceptual work, because it pointed attention at the fatty material itself as the heart of the process, anticipating the lipid research that would follow.

The Greek root athērē had already been used for centuries: early anatomists called a fatty cyst or fatty arterial deposit an "atheroma" precisely because the cheesy yellow paste that oozed from it on cutting looked like porridge or gruel. So when you read "atheroma" (a single plaque), "atherosclerosis" (the disease), and "arteriosclerosis" (the general category of arterial hardening), you are reading three layers of a naming history laid down between classical antiquity and the early twentieth century. To be precise and honest: these were acts of naming and classifying what pathologists saw under the knife and the microscope, not claims to have discovered the disease's cause — the cause was, and to some degree still is, the harder question.

Back to Table of Contents

Early Anatomy: From Leonardo to the First Descriptions

Long before the disease had a name, careful observers were drawing and describing the changes that age writes into arteries. Leonardo da Vinci (1452–1519), dissecting human cadavers around 1500, left anatomical notes and drawings remarking on the thickening and tortuosity of arteries in the elderly, and is often credited as among the first to associate vessel changes with aging and with restricted blood flow. Whether his observations amount to a true description of atherosclerosis is debated by historians, so he is best cited as an early and acute observer rather than a discoverer.

Through the seventeenth and eighteenth centuries, the new science of morbid anatomy — the systematic study of diseased organs after death — brought the arteries into clearer focus. The Italian anatomist Giovanni Battista Morgagni (1682–1771), whose 1761 masterwork De Sedibus et Causis Morborum founded pathological anatomy as a discipline, described hardened, dilated, and "ossified" arteries among the elderly dead and tried to link such findings to the symptoms patients had suffered in life. Albrecht von Haller is credited with using the word atheroma for arterial deposits in this same era, and the English anatomist Joseph Hodgson, early in the nineteenth century, argued that inflammation lay at the root of the arterial changes — a remarkably modern idea for its time.

By the early 1800s, then, the raw observations were in place: arteries grow stiff, thickened, and clogged with a fatty, sometimes chalky material, and this is somehow connected to disease and death. What was missing was a coherent theory of why — and that is exactly what the great pathologists of the mid-nineteenth century set out to provide, in one of the most consequential scientific arguments in the history of medicine.

Back to Table of Contents

The Great Debate: Virchow versus Rokitansky

The middle of the nineteenth century saw a genuine, sharp, and historically important disagreement between two of the greatest pathologists who ever lived — and it is essential to present it as a real debate, not a settled fact handed down by one authority. On one side stood the Austrian Carl von Rokitansky (1804–1878) in Vienna; on the other, the German Rudolf Virchow (1821–1902) in Berlin. They proposed fundamentally different explanations for how a plaque forms.

Rokitansky advanced what became known as the encrustation (or thrombogenic) hypothesis. In his view, the plaque originated in the blood: small deposits of fibrin and other blood elements were laid down on the inner arterial surface, like crust on a pipe, and the vessel wall's response to these incorporated micro-thrombi was secondary. Virchow disagreed forcefully. Drawing on his cell-based view of disease (he was the architect of cellular pathology and famous for the dictum omnis cellula e cellula — every cell from a cell), Virchow argued in the 1850s and 1860s that the plaque grew from within the vessel wall itself: an active, irritative, inflammatory and proliferative process of the arterial intima, in which cells multiplied, took up fatty material, and died. He saw atherosclerosis as something the artery does, not merely something deposited on it.

For much of the twentieth century Virchow's "inflammation" emphasis fell out of fashion in favor of a simpler picture of passive lipid accumulation. The honest modern verdict, however, is that both men were partly right. Today's understanding folds together Virchow's insight that atherosclerosis is an active inflammatory, cellular process within the wall and Rokitansky's insight that thrombus material incorporated from the blood contributes to the growth of advanced plaque. Their nineteenth-century quarrel turns out to have anticipated a synthesis that medicine would not fully reach for another 150 years.

Back to Table of Contents

Anitschkow, the Rabbit, and the Lipid Hypothesis

If one experiment can be called the foundation stone of modern atherosclerosis research, it is the rabbit work of the young Russian pathologist Nikolai Nikolaievich Anitschkow (1885–1964) in St. Petersburg. In 1913, building on earlier feeding experiments, Anitschkow — working with his student S. Chalatow — purified cholesterol from egg yolks, dissolved it in sunflower oil, and fed it to ordinary rabbits. Their blood cholesterol rose sharply, and within weeks their arteries developed fatty, raised lesions that closely resembled human atherosclerotic plaque. By feeding pure cholesterol, he isolated the responsible agent.

This was a real advance over the prevailing idea of the day. A few years earlier, Alexander Ignatowsky had produced arterial lesions in rabbits fed animal products (meat, milk, eggs) and attributed the damage to "protein intoxication." Anitschkow's controlled experiments showed it was the cholesterol specifically, not protein, that drove the lesions, and that the amount of disease tracked the amount of cholesterol fed. Examining the plaques, he also described the cell types — lipid-laden macrophages, smooth muscle cells, and other elements — that remain central to atherosclerosis research today. His conclusion is sometimes paraphrased as "without cholesterol, no atherosclerosis."

It is important to frame this carefully and honestly. Anitschkow's work is the experimental origin of the lipid hypothesis — the proposal that cholesterol and other lipids are central to causing atherosclerosis — and for decades it was treated by many as just that, a hypothesis. For years his findings were neglected, partly because the cholesterol-fed rabbit is an imperfect stand-in for human disease and partly because the implications were resisted. Only across the rest of the twentieth century, as autopsy series, population studies, genetics, and ultimately drug trials accumulated, did the central role of lipids move from contested hypothesis toward established cause. The 2013 centenary of his paper was marked precisely because the idea he launched had, by then, been so thoroughly borne out.

Back to Table of Contents

Epidemiology and the Risk-Factor Era

Laboratory experiments could show that cholesterol caused plaque in rabbits, but proving what drives heart attacks in living human populations required a different tool: long-term observation of large groups of ordinary people. The landmark effort was the Framingham Heart Study, begun in 1948 in the town of Framingham, Massachusetts, which enrolled thousands of healthy residents and followed them for decades to see who developed cardiovascular disease and why. It was Framingham that, in 1961, popularized the very phrase "risk factor."

The risk-factor framework reshaped medicine. Framingham and the studies that followed identified high blood cholesterol, high blood pressure, cigarette smoking, diabetes, and (later) physical inactivity and obesity as the major, often modifiable, contributors to atherosclerotic disease — the conditions covered across this site's cardiology and metabolic pages. In parallel, the physiologist Ancel Keys launched the international Seven Countries Study in the late 1950s, comparing diet, blood cholesterol, and heart-disease rates across populations and arguing for a link between dietary fat, serum cholesterol, and coronary heart disease.

This epidemiology was decisive in moving the lipid hypothesis from the laboratory bench toward public health, but it also carried real historical controversy that should be acknowledged plainly. Keys's diet-heart conclusions were contested at the time and have been re-debated since, including criticism of how countries were selected and of the relative emphasis on dietary fat versus sugar and other factors. The fair summary is that population studies established that cholesterol, blood pressure, smoking, and diabetes are powerful predictors of atherosclerotic disease, while the precise dietary details remained — and to some extent remain — a live scientific argument.

Back to Table of Contents

Response to Injury and the Return of Inflammation

By the 1970s the dominant picture of atherosclerosis was largely passive: lipids, present in excess, simply infiltrated and accumulated in the arterial wall. Two American scientists at the University of Washington, the pathologist Russell Ross (1929–1999) and his colleague John Glomset, proposed a more dynamic explanation. In 1973 they articulated the "response-to-injury hypothesis," arguing that atherosclerosis begins with injury to the delicate endothelial lining of the artery — from forces such as high blood pressure, toxins from smoking, or modified cholesterol particles — and that the plaque is the artery's healing response to that repeated injury, gone wrong.

The hypothesis was tested, criticized, and repeatedly revised over the following quarter-century, which is exactly how a good scientific hypothesis is supposed to behave. Its most influential mature form arrived in Ross's 1999 New England Journal of Medicine review, bluntly titled "Atherosclerosis — An Inflammatory Disease." Here the lipid story and the inflammation story were finally fused: cholesterol particles enter the injured wall and are modified (for example, oxidized); immune cells called monocytes are recruited, become macrophages, engulf the cholesterol, and turn into lipid-stuffed foam cells; and a self-sustaining chronic inflammation builds the plaque over years. In a real sense this vindicated Virchow's mid-nineteenth-century intuition that atherosclerosis is fundamentally an inflammatory, cellular process of the vessel wall.

That inflammation is genuinely part of the disease — not merely a theory — gained powerful clinical support in 2017, when the CANTOS trial showed that an anti-inflammatory antibody (canakinumab) targeting interleukin-1β, given on top of standard therapy, reduced cardiovascular events independently of any change in cholesterol. The history therefore runs full circle: an inflammatory idea proposed in the 1850s, eclipsed by the lipid focus of the early 1900s, revived as a hypothesis in the late twentieth century, and confirmed by experiment in the twenty-first.

Back to Table of Contents

From Hypothesis to Therapy: The Statin Story

A cause is most convincingly proven when removing it prevents the disease — and that final, decisive chapter belongs to the statins. The story begins with the Japanese biochemist Akira Endo (1933–2024), who in the early 1970s, while at the pharmaceutical company Sankyo, set out to find a natural compound that would block HMG-CoA reductase, the rate-limiting enzyme the body uses to manufacture cholesterol. After screening thousands of fungal cultures, Endo isolated the first such inhibitor, compactin (ML-236B), from the mold Penicillium citrinum in 1976. It was the first statin — a drug that lowers cholesterol by throttling its synthesis in the liver.

Endo's discovery, often compared in importance to the discovery of penicillin, opened a new class of medicines. Building on it, the first statin approved for wide use, lovastatin, reached patients in 1987, followed by simvastatin, pravastatin, atorvastatin, and others. The crucial historical point is what these drugs allowed researchers to do: run large randomized controlled trials that lowered cholesterol in one group and not another and then counted heart attacks, strokes, and deaths. Landmark trials in the 1990s, beginning with the 1994 Scandinavian Simvastatin Survival Study (4S), showed that lowering LDL cholesterol with a statin clearly reduced cardiovascular events and saved lives.

This is the moment the lipid hypothesis ceased to be merely a hypothesis about atherosclerosis. Anitschkow had shown in 1913 that feeding cholesterol caused arterial lesions in rabbits; eighty years later, trials showed that pharmacologically lowering cholesterol prevented cardiovascular events in people. The cumulative arc — ancient mummies, Lobstein's and Marchand's naming, the Virchow–Rokitansky debate, Anitschkow's rabbits, the risk-factor epidemiology, Ross's response-to-injury and inflammation synthesis, and finally Endo's statins — is the story of how a very old, no-single-inventor disease came to be understood and, at last, partly controlled. The practical side of that control — lipid management, blood-pressure control, and lifestyle — is covered in the companion pages linked below.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical reviews and primary reports (with DOIs or PMIDs where confidently identified) with curated PubMed topic-search links into the historical and pathological literature. Historical primary works named in the article — Lobstein's Traité d'anatomie pathologique (1833), Morgagni's De Sedibus et Causis Morborum (1761), and the original papers of Virchow, Rokitansky, and Anitschkow — are cited as historical sources rather than as live links. Each link opens at its publisher or at PubMed (National Library of Medicine) in a new tab.

  1. Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. The Lancet. 2013;381(9873):1211-1222. — doi:10.1016/S0140-6736(13)60598-X
  2. Allam AH, Thompson RC, Wann LS, et al. Atherosclerosis in ancient Egyptian mummies: the Horus study. JACC: Cardiovascular Imaging. 2011;4(4):315-327. — doi:10.1016/j.jcmg.2011.02.002
  3. Mehta NJ, Khan IA. Cardiology's 10 greatest discoveries of the 20th century. Texas Heart Institute Journal. 2002;29(3):164-171. — PMID: 12224718
  4. Mayerl C, Lukasser M, Sedivy R, et al. Atherosclerosis research from past to present — on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Archiv. 2006;449(1):96-103. — doi:10.1007/s00428-006-0176-7
  5. Konstantinov IE, Mejevoi N, Anichkov NM. Nikolai N. Anichkov and his theory of atherosclerosis. Texas Heart Institute Journal. 2006;33(4):417-423. — PMID: 17215962
  6. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. Journal of Lipid Research. 2013;54(11):2946-2949. — doi:10.1194/jlr.R043414
  7. Ross R. Atherosclerosis — an inflammatory disease. New England Journal of Medicine. 1999;340(2):115-126. — doi:10.1056/NEJM199901143400207
  8. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). New England Journal of Medicine. 1976;295(7):369-377. — doi:10.1056/NEJM197608122950707
  9. Endo A. A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B. 2010;86(5):484-493. — doi:10.2183/pjab.86.484
  10. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). New England Journal of Medicine. 2017;377(12):1119-1131. — doi:10.1056/NEJMoa1707914
  11. History and etymology of the terms atheroma, atherosclerosis, and arteriosclerosis — PubMed: history of atherosclerosis terminology
  12. Virchow, inflammation, and the pathogenesis of atherosclerosis — PubMed: Virchow, inflammation, and atherosclerosis
  13. Framingham Heart Study and the origin of the "risk factor" concept — PubMed: Framingham Heart Study and the risk-factor concept
  14. Ancel Keys, the Seven Countries Study, and the diet-heart debate — PubMed: Ancel Keys and the Seven Countries Study

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents